RAPT Live signals | Maximize Profits with Getagraph.com

SELL 139635 min ago

@ $24.99

Issued: 13 Feb 2024 @ 15:43

Return: -83.99%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: 0.73 %

Live Chart Being Loaded With Signals

Commentary (20 May 2024 @ 15:59):

Stats
Today's Volume	627 115
Average Volume	1.33M
Market Cap	139.61M
EPS	$0 ( 2024-05-09 )
Next earnings date	( $-0.810 ) 2024-05-22
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.300
ATR14	$0.00800 (0.20%)

Insider Trading

Date	Person	Action	Amount	type
2024-03-28	Robbins Wendye	Buy	6 925	Stock Option (right to buy)
2024-03-28	Gray Mary Ann	Buy	8 574	Stock Option (right to buy)
2024-03-28	Rieflin William Jl	Buy	11 871	Stock Option (right to buy)
2024-01-31	Ho William	Buy	75 000	Employee Stock Option (right to buy)
2024-01-31	Young Rodney Kb	Buy	90 000	Employee Stock Option (right to buy)

INSIDER POWER
93.66
Last 100 transactions
Buy: 3 742 359 \| Sell: 63 895

Volume Correlation

Long: -0.08 (neutral)

Short: 0.40 (neutral)

Signal:(55.997) Neutral

Rapt Therapeutics Inc Correlation

10 Most Positive Correlations
CYAN	0.945
LTRX	0.943
QDEL	0.94
WISA	0.938
IMKTA	0.938
SSRM	0.932
HFFG	0.931
VLCN	0.93
KRKR	0.93
AMCX	0.93

10 Most Negative Correlations
MACK	-0.978
MEDP	-0.953
ADSE	-0.95
CRTO	-0.932
IBKR	-0.928
TXRH	-0.927
FREE	-0.927
SHLD	-0.921
TRVI	-0.917
VSEC	-0.917

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Rapt Therapeutics Inc Correlation - Currency/Commodity

-0.09
( neutral )

0.01
( neutral )

0.00
( neutral )

-0.22
( neutral )

-0.57
( weak negative )

0.27
( neutral )

Rapt Therapeutics Inc Financials

Annual	2023
Revenue:	$0
Gross Profit:	$-3.55M (0.00 %)
EPS:	$-3.05

FY	2023
Revenue:	$0
Gross Profit:	$-3.55M (0.00 %)
EPS:	$-3.05

FY	2022
Revenue:	$1.53M
Gross Profit:	$-1.28M (-83.82 %)
EPS:	$-2.52

FY	2021
Revenue:	$3.81M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-2.53

Financial Reports:

No articles found.

Rapt Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Rapt Therapeutics Inc

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Realtime updates for Rapt Therapeutics Inc [RAPT]

Upcoming Earnings Alert

Rapt Therapeutics Inc Options Data

Calls

Puts